Charles Sawyers, M.D., is an investigator for the Howard Hughes Medical Institute, the Marie-Josée and Henry R. Kravis Chair in Human Oncology and Pathogenesis, and Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center.
A leading researcher in molecularly targeted approaches to treat cancer, Dr. Sawyers has identified cell signaling components critical to the growth of cancer cells in chronic myeloid leukemia, prostate cancer and other cancers. His efforts have led to the development of multiple FDA-approved inhibitors in clinical use today, including imatinib for the treatment of chronic myeloid leukemia and the antiandrogen drug enzalutamide for the treatment of advanced prostate cancer.
Dr. Sawyers received a B.A. from Princeton University and an M.D. from Johns Hopkins University School of Medicine. He is a former president of the American Association for Cancer Research (AACR), a member of the 2014 class of Fellows of the AACR Academy, and former president of AACR Academy.